IPO registrations (S-1, F-1) · Registrants
Century Therapeutics, Inc.
- SEC CIK
- 1850119 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-05-28, last 2021-06-15; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2021-06-21; declared effective 2021-06-17
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 25 N 38TH STREET, 12TH FLOOR, Philadelphia, PA
- EIN
- 84-2040295
- Ticker
- IPSC (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Century Therapeutics, Inc. on the corporate pages
Offering terms
- Proposed price range
- $18.00–$20.00 per share (S-1/A filed 2021-06-15)
- Final price
- $20.00 per share, within the range (424B4 filed 2021-06-21, an initial public offering)
- Shares sold
- 10,550,000
- Gross proceeds
- $211,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol IPSC
- Lead underwriters
- J.P. Morgan; BofA Securities; Leerink Partners; Piper Sandler
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Century Therapeutics, Inc. Fuzzy (name and state)
- Form 5500 plan sponsor: CENTURY THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: Century Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: Century Therapeutics, Inc. EXACT (CIK (EXACT))
- Person page: Timothy P Walbert Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-05-28 | S-1 | S-1 (registration) | Century Therapeutics, Inc. | 0001104659-21-074278 ↗ |
| 2021-06-14 | S-1/A | S-1/A (amendment) | Century Therapeutics, Inc. | 0001104659-21-080429 ↗ |
| 2021-06-15 | S-1/A | S-1/A (amendment) | Century Therapeutics, Inc. | 0001104659-21-081561 ↗ |
| 2021-06-17 | EFFECT | EFFECT (declared effective) | Century Therapeutics, Inc. | 9999999995-21-002398 ↗ |
| 2021-06-21 | 424B4 | 424B4 (final prospectus) | Century Therapeutics, Inc. | 0001104659-21-082886 ↗ |
| 2022-07-13 | EFFECT | EFFECT (declared effective) | Century Therapeutics, Inc. | 9999999995-22-002060 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-06-15 | S-1/A | registration statement | $18.00–$20.00 | 10,550,000 | - | Nasdaq IPSC | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2021-06-21 | 424B4 | final prospectus | $20.00 | 10,550,000 | $211,000,000 | Nasdaq IPSC | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BAYER AKTIENGESELLSCHAFT | TenPercentOwner | 2 | 2021 | ||
| Bayer World Investments B.V. | TenPercentOwner | 2 | 2021 | ||
| Blackwell Kimberly | Director | 7 | 2021–2026 | ||
| Borges Luis | Officer | Chief Scientific Officer | 5 | 2021–2023 | |
| BUTITTA CYNTHIA M | Director | 6 | 2021–2025 | ||
| Carlo Rizzuto | Director | 6 | 2021–2025 | ||
| Carr Douglas | Officer | SVP Finance & Operations; VP Finance & Operations; VP of Finance and Operations | 29 | 2021–2026 | |
| Casdin Eli | Director | 4 | 2021–2022 | ||
| Diem Michael Craig | Officer | Chief Business Officer; Chief Financial Officer | 5 | 2021–2023 | |
| Farid Adrienne | Officer | Chief Operations Officer | 14 | 2021–2025 | |
| Flores Osvaldo | Director,Officer; Officer | Chief Executive Officer | 3 | 2021–2023 | |
| FUJIFILM Cellular Dynamics, Inc. | TenPercentOwner | 2 | 2021 | ||
| FUJIFILM Corp | TenPercentOwner | 2 | 2021 | ||
| FUJIFILM Holdings America Corp | TenPercentOwner | 2 | 2021 | ||
| FUJIFILM Holdings Corp | TenPercentOwner | 2 | 2021 | ||
| JIMENEZ JOSEPH | Director | 6 | 2021–2025 | ||
| Levitsky Hyam | Officer | President of R&D | 5 | 2021–2024 | |
| Riva Alessandro | Director | 7 | 2021–2026 | ||
| Russotti Gregory | Officer | Chief Technology Officer; See Remarks | 23 | 2021–2026 | |
| Versant Vantage II GP-GP, LLC | TenPercentOwner | 5 | 2021–2022 | ||
| Versant Vantage II GP, L.P. | TenPercentOwner | 5 | 2021–2022 | ||
| Versant Vantage II, L.P. | TenPercentOwner | 5 | 2021–2022 | ||
| Versant Venture Capital VI, L.P. | TenPercentOwner | 5 | 2021–2022 | ||
| Versant Ventures VI GP-GP, LLC | TenPercentOwner | 5 | 2021–2022 | ||
| Versant Ventures VI GP, L.P. | TenPercentOwner | 5 | 2021–2022 | ||
| Quimi Daphne | Director | 7 | 2022–2026 | ||
| Walbert Timothy P | Director | 5 | 2022–2025 | person page Fuzzy | |
| Pfeiffenberger Brent | Director,Officer | President and CEO | 24 | 2023–2026 | |
| Cowan Chad | Officer | Chief Scientific Officer | 11 | 2024–2026 | |
| Conn Morgan | Officer | Chief Financial Officer; Chief Finanical Officer | 3 | 2024–2025 | |
| Lee Han Myung | Director | 3 | 2025–2026 | ||
| Murphy Martin Patrick | Director | 3 | 2026 | ||
| Truitt Joseph | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-03-15 | Century Therapeutics, Inc. | Other Health Care | $160,000,000 | $0 | 22 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Century Therapeutics, Inc. | PA | State business registries | name and state |
| Plan sponsor | CENTURY THERAPEUTICS, INC. | PA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Century Therapeutics, Inc. | PA | Form D private offerings | CIK (EXACT) |
| Patent assignee | Century Therapeutics, Inc. | PA | Patents (USPTO) | name and state |
| SEC filer | Century Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Century Therapeutics, Inc. | PA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | CENTURY THERAPEUTICS, INC. | EIN (EXACT) | ||
| Person page | Timothy P Walbert | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), PA first:
- APOLLON INC PA
- Aevi Genomic Medicine, LLC PA
- Ocugen, Inc. PA
- Spark Therapeutics, Inc. PA
- Krystal Biotech, Inc. PA
- Cabaletta Bio, Inc. PA
- Passage BIO, Inc. PA
- Aphton CORP PA
- Aceragen, Inc. PA
- GENAERA CORP PA
In other datasets, the same topic (Health) in PA:
- Nonprofit: 445 FOUNDATION (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health